During EMT, polarized epithelial cells acquire mesenchymal characteristics through loss of cell‐cell adhesion and apical‐basal polarity.[5] Vimentin, a type III intermediate filament protein, serves as a biomarker of aggressive phenotypes across multiple carcinomas.[6] Clinical evidence from breast, lung, esophageal, gastric, and colorectal cancers consistently demonstrates positive correlations between vimentin expression and metastatic progression(6). The gene discussed is VIM; the disease is colorectal cancer.